Search for: "ASTRAZENECA LP" Results 41 - 60 of 159
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
14 May 2013, 6:18 pm by Mark Zamora
 The lawsuits in the Nexium MDL claim that Nexium, created by manufacturer, AstraZeneca LP, causes side effects such as bone loss, which subsequently has resulted in fractures and similar symptoms. [read post]
24 Mar 2013, 8:01 pm by Patent Docs
Watson Laboratories, Inc. - Florida et al. 3:13-cv-01669; filed March 19, 2013 in the District Court of New Jersey • Plaintiffs: AstraZeneca AB; Aktiebolaget Hassle; AstraZeneca LP; KBI Inc.; KBI-E Inc. [read post]
10 Sep 2012, 7:28 pm by FDABlog HPM
In July, after a court battle with FDA that started around mid-March when AstraZeneca Pharmaceuticals LP (“AstraZeneca”) sought to enjoin FDA from granting final ANDA approvals for generic SEROQUEL following FDA’s denial (without comment) of two citizen petitions AstraZeneca submitted to FDA last year concerning labeling carve-out issues, the U.S. [read post]
9 Jul 2012, 7:41 pm by FDABlog HPM
Karst –  In a decision that, unless appealed, marks the end of AstraZeneca Pharmaceuticals LP’s (“AstraZeneca’s”) battle with FDA over the approval of generic versions of the company’s blockbuster antipsychotic drug SEROQUEL (quetiapine fumarate) Tablets, the U.S. [read post]
15 Jun 2012, 12:19 pm by Schachtman
AstraZeneca LP, 2009 WL 1610575 at 8 (Del. [read post]
8 Jun 2012, 5:00 am
On May 30, AstraZeneca Pharmaceuticals LP ("AstraZeneca") reached an agreement to a settlement with a class of indirect purchasers in an antitrust action involving the drug Toprol-XL® (metoprolol succinate) in Delaware. [read post]
25 May 2012, 11:32 am by Robert Vrana
  Judge Stark cited the Federal Circuit’s recent decision in AstraZeneca Pharmaceuticals LP v. [read post]
16 May 2012, 12:22 pm by Bexis
AstraZeneca Pharmaceuticals, LP, 634 F.3d 1352, 1360-66 (11th Cir. 2011) (plaintiff had not pleaded recoverable economic injury); Polk v. [read post]
16 Apr 2012, 1:29 am by FDABlog HPM
District Court are Motions for Summary Judgment filed by FDA and AstraZeneca Pharmaceuticals LP (here and here) concerning FDA’s approval of ANDAs for generic versions of SEROQUEL (quetiapine fumarate) Tablets and the Agency’s decision, discussed in a March 27, 2012 Letter Decision, concerning the scope and applicability of 3-year marketing exclusivity in that case. [read post]
29 Mar 2012, 5:47 am by FDABlog HPM
District Court for the District of Columbia denied AstraZeneca Pharmaceuticals LP’s (“AstraZeneca’s”) Motion for Temporary Restraining Order (Complaint here) seeking to vacate FDA’s March 27, 2012 approval of more than 10 ANDAs for generic versions of AstraZeneca’s blockbuster antipsychotic drug SEROQUEL (quetiapine fumarate) Tablets (NDA No. 020639), and to enjoin FDA from granting any further final ANDA approvals for the drug… [read post]